FDG-PET in the Diagnosis of Autoimmune Encephalitis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: FDG-PET.
- Who it may be relevant to
- Registry conditions: Autoimmune Encephalitis. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The goal of this retrospective observational study is to compare brain fluorodeoxyglucose-positron emission tomography (FDG-PET) of patients with autoimmune encephalitis, normal controls and patients with Alzheimer's disease (AD). The main question it aims to answer is: •is there a specific pattern of brain metabolism in patients with autoimmune encephalitis Participants data and images will be retrospectively collected from hospital records, and FDG-PET images will be analyzed by means of statistical parametric mapping (SPM). Controls will be selected from validated public databases.
Interventions
- Diagnostic test FDG-PET
Brain FDG-PET
Primary outcome measures
- SPM analysis of brain metabolic pattern [Time frame: up to 6 months]
Secondary outcome measures (2)
- Sensitivity of basal ganglia hypermetabolism [Time frame: up to 6 months]
- Diagnostic delay [Time frame: up to 6 months]
Eligibility criteria
Inclusion criteria
- Diagnosis of autoimmune encephalitis according to clinical criteria
- Brain magnetic resonance imaging performed between clinical presentation and treatment
- Cerebrospinal fluid analysis performed between clinical presentation and treatment
- Brain FDG-PET performed between clinical presentation and treatment
- Autoantibodies testing performed between clinical presentation and treatment
Exclusion criteria
- Refusal to give consent for the study
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Italy · 6 centers
- Azienda Sanitaria Universitaria Friuli Centrale — Udine
- IRCCS Ospedale Policlinico San Martino — Genoa
- Fondazione IRCCS Mondino — Pavia
- Fondazione IRCCS Istituto Neurologico "Carlo Besta" — Milan
- Ospedale San Paolo — Milan
- Fondazione IRCCS San Gerardo dei Tintori — Monza
Identifiers
NCT: NCT06019975 · PEA